Clinical Trial: Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

Brief Summary: The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alström syndrome.